KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Jazz Pharmaceuticals (JAZZ) Operating Leases (2019 - 2025)

Historic Operating Leases for Jazz Pharmaceuticals (JAZZ) over the last 8 years, with Q3 2025 value amounting to $53.4 million.

  • Jazz Pharmaceuticals' Operating Leases fell 2487.38% to $53.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $53.4 million, marking a year-over-year decrease of 2487.38%. This contributed to the annual value of $38.9 million for FY2024, which is 3425.41% down from last year.
  • Latest data reveals that Jazz Pharmaceuticals reported Operating Leases of $53.4 million as of Q3 2025, which was down 2487.38% from $55.1 million recorded in Q2 2025.
  • Jazz Pharmaceuticals' Operating Leases' 5-year high stood at $177.1 million during Q2 2021, with a 5-year trough of $38.8 million in Q1 2025.
  • In the last 5 years, Jazz Pharmaceuticals' Operating Leases had a median value of $71.1 million in 2024 and averaged $77.2 million.
  • As far as peak fluctuations go, Jazz Pharmaceuticals' Operating Leases tumbled by 5603.29% in 2022, and later soared by 1490.18% in 2024.
  • Quarter analysis of 5 years shows Jazz Pharmaceuticals' Operating Leases stood at $87.2 million in 2021, then dropped by 17.62% to $71.8 million in 2022, then dropped by 17.56% to $59.2 million in 2023, then crashed by 34.25% to $38.9 million in 2024, then soared by 37.21% to $53.4 million in 2025.
  • Its last three reported values are $53.4 million in Q3 2025, $55.1 million for Q2 2025, and $38.8 million during Q1 2025.